Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults (COVID-19 Vaccine Study in Minnesota)
Principal Investigators: Charlene McEvoy, MD, MPH; Zeke McKinney, MD
Study sponsor: AstraZeneca
Location: Bloomington, MN
Phase of Study: Phase III
Purpose of study: The AstraZeneca COVID-19 vaccine study is a clinical research study to evaluate an investigational vaccine for the prevention of COVID-19. In this study, participants will be randomly assigned (by chance) to receive 2 injections of either the investigational vaccine or placebo (4 weeks apart). A placebo looks like the investigational vaccine but contains no active vaccine. There is twice as much chance of receiving the investigational vaccine than of receiving the placebo. Study participation will last about 2 years.
-At least 18 years of age
-Are in good or stable health, including having a well-managed underlying medical condition
-Have an increased risk of getting COVID-19, like working in a close-contact profession
-Don’t have a previously confirmed COVID-19 diagnosis
Visit https://www.healthpartners.com/vaccinestudy for more information about the study and to complete the screening form.